These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37258313)

  • 21. Prostate-specific antigen, prostate cancer screening, and the pathologist: what should be our role?
    Jackson BR
    Arch Pathol Lab Med; 2013 Mar; 137(3):308-9. PubMed ID: 22799565
    [No Abstract]   [Full Text] [Related]  

  • 22. Variation of colorectal, breast and prostate cancer screening activity in Switzerland: Influence of insurance, policy and guidelines.
    Ulyte A; Wei W; Dressel H; Gruebner O; von Wyl V; Bähler C; Blozik E; Brüngger B; Schwenkglenks M
    PLoS One; 2020; 15(4):e0231409. PubMed ID: 32298325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Frequency of Guideline-Discordant Prostate Cancer Screening Among Older Males.
    Kensler KH; Mao J; Davuluri M
    JAMA Netw Open; 2024 Apr; 7(4):e248487. PubMed ID: 38662374
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ERSPC and PLCO prostate cancer screening studies: what are the differences?
    Schröder FH; Roobol MJ
    Eur Urol; 2010 Jul; 58(1):46-52. PubMed ID: 20362385
    [No Abstract]   [Full Text] [Related]  

  • 25. Storm over screening for prostate specific antigen. Number needed to test needs to be known.
    de Lemos ML
    BMJ; 2002 Jun; 324(7350):1392. PubMed ID: 12053925
    [No Abstract]   [Full Text] [Related]  

  • 26. USPTF Prostate Cancer Screening Recommendations-A Step in the Right Direction.
    Carroll PR
    JAMA Surg; 2018 Aug; 153(8):701-702. PubMed ID: 29801146
    [No Abstract]   [Full Text] [Related]  

  • 27. [Screening for prostate cancer using prostate-specific antigen (PSA) : A commentary on a systematic review and meta-analysis].
    Borkowetz A
    Urologe A; 2019 Aug; 58(8):925-928. PubMed ID: 31240375
    [No Abstract]   [Full Text] [Related]  

  • 28. Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study.
    Carlsson S; Assel M; Sjoberg D; Ulmert D; Hugosson J; Lilja H; Vickers A
    BMJ; 2014 Mar; 348():g2296. PubMed ID: 24682399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. What the U.S. Preventive Services Task Force missed in its prostate cancer screening recommendation.
    Catalona WJ; D'Amico AV; Fitzgibbons WF; Kosoko-Lasaki O; Leslie SW; Lynch HT; Moul JW; Rendell MS; Walsh PC
    Ann Intern Med; 2012 Jul; 157(2):137-8. PubMed ID: 22801676
    [No Abstract]   [Full Text] [Related]  

  • 30. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Pinsky PF; Blacka A; Kramer BS; Miller A; Prorok PC; Berg C
    Clin Trials; 2010 Aug; 7(4):303-11. PubMed ID: 20571134
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is Prostate-Specific Antigen Screening "Proven Ineffective Care"?
    Barry MJ; Albertsen PC
    Ann Intern Med; 2016 May; 164(10):687-8. PubMed ID: 26902323
    [No Abstract]   [Full Text] [Related]  

  • 32. Re: National Prostate Cancer Screening Rates after the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening.
    Taneja SS
    J Urol; 2016 Feb; 195(2):350-1. PubMed ID: 26852972
    [No Abstract]   [Full Text] [Related]  

  • 33. National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening.
    Drazer MW; Huo D; Eggener SE
    J Clin Oncol; 2015 Aug; 33(22):2416-23. PubMed ID: 26056181
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate-Specific Antigen Screening After 2012 US Preventive Services Task Force Recommendations.
    Sammon JD; Abdollah F; Choueiri TK; Kantoff PW; Nguyen PL; Menon M; Trinh QD
    JAMA; 2015 Nov; 314(19):2077-9. PubMed ID: 26575066
    [No Abstract]   [Full Text] [Related]  

  • 35. Rates of clinically significant prostate cancer in African Americans increased significantly following the 2012 US Preventative Services Task Force recommendation against prostate specific antigen screening: A Single Institution Retrospective Study.
    Arace J; Flores V; Monaghan T; Robins D; Karanikolas N; Winer A; Weiss J
    Int J Clin Pract; 2020 Feb; 74(2):e13447. PubMed ID: 31750596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic factors of prostate cancer mortality in a Finnish randomized screening trial.
    Neupane S; Steyerberg E; Raitanen J; Talala K; Pylväläinen J; Taari K; Tammela TL; Auvinen A
    Int J Urol; 2018 Mar; 25(3):270-276. PubMed ID: 29224236
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate specific antigen for detecting early prostate cancer.
    Ilic D; Green S
    BMJ; 2009 Sep; 339():b3572. PubMed ID: 19778970
    [No Abstract]   [Full Text] [Related]  

  • 38. Alternative prostate cancer screening strategies.
    Labrecque M; Aprikian A
    Ann Intern Med; 2013 May; 158(10):778. PubMed ID: 23689773
    [No Abstract]   [Full Text] [Related]  

  • 39. Discuss prostate cancer screening with your doctor.
    The Lancet
    Lancet; 2017 Apr; 389(10079):1582. PubMed ID: 28443541
    [No Abstract]   [Full Text] [Related]  

  • 40. Detection rate of prostate cancer following biopsy among the northern Han Chinese population: a single-center retrospective study of 1022 cases.
    Jia Y; Zhu LY; Xian YX; Sun XQ; Gao JG; Zhang XH; Hou SC; Zhang CC; Liu ZX
    World J Surg Oncol; 2017 Aug; 15(1):165. PubMed ID: 28851376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.